List view / Grid view
20 May 2014 | By Galderma
Galderma announced that ACTINICA® Lotion is now available for the prevention of non-melanoma skin cancer in high risk patients, including those who have had an organ transplant, undergone chemotherapy for malignant disease or have HIV/AIDS...
20 May 2014 | By Lundbeck
H. Lundbeck A/S is involved in new research on Parkinson’s disease, which may be the first step towards a new and significantly improved treatment of the debilitating and devastating disease...
20 May 2014 | By Cancer Research UK
CANCER RESEARCH UK scientists have shown how switching off a key protein in pancreatic cells slows the spread of the disease to other tissues, a key step which can mean patients have just weeks to live...
20 May 2014 | By Merck
Merck Millipore announced that Bonnie Bassler, Ph.D., Squibb Professor and Chair of the Department of Molecular Biology, Princeton University, has won the 2014 Merck Millipore Alice C. Evans Award for Leadership in Clinical Microbiology...
20 May 2014 | By GlaxoSmithKline
GlaxoSmithKline plc presented data at the American Thoracic Society (ATS) from a late-stage clinical study...
20 May 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company and AbbVie announced that the U.S. Food and Drug Administration has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone...
20 May 2014 | By Boehringer Ingelheim
Data analyses presented at the Annual American Thoracic Society International Conference 2014 reconfirm the efficacy of SPIRIVA® (tiotropium) in reducing the risk of COPD exacerbations...
20 May 2014 | By AstraZeneca
The Board of AstraZeneca PLC notes the announcement by Pfizer Inc. of its final proposal, comprising £24.76 in cash (45%) and 1.747 Pfizer shares (55%) per AstraZeneca share, representing a value of £55.00 per AstraZeneca share (based on the closing price of Pfizer shares on 16 May 2014...
20 May 2014 | By Novartis
Novartis announced the signing of a licensing and commercialization agreement with Ophthotech Corporation for the exclusive rights to market Fovista® outside the United States...
Scientists analyzing non-conductive, high-purity materials will soon be able to apply powerful high-resolution glow discharge mass spectrometry (GDMS) to this task. This will open the technique, for example, to analysis of high-purity sapphire used for flat panel displays, ceramics, alumina powder and other desirable applications, including thin-layer depth profiling of…
19 May 2014 | By Roche
Roche announced plans to invest a total of 120 million Swiss francs in the construction of new production facilities in Building 50, an existing building at its Basel site...
19 May 2014 | By Janssen Pharmaceutical Companies
Janssen-Cilag International NV today announced that its next generation protease inhibitor OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission for the treatment of adults with genotype 1 and 4 chronic hepatitis C...
19 May 2014 | By The European Medicines Agency
The European Medicines Agency’s Committee for Advanced Therapies and the German Society for Transfusion Medicine and Immunohaematology in collaboration with the German Stem Cell Network are organising a workshop to strengthen dialogue...
19 May 2014 | By AbbVie
AbbVie has named Michael Severino, M.D. its new Executive Vice President, Research and Development and Chief Scientific Officer...
19 May 2014 | By Boehringer Ingelheim
Results from the Phase III INPULSIS™ trials, published online in the New England Journal of Medicine, show nintedanib* significantly slowed disease progression in patients with idiopathic pulmonary fibrosis...
